COLA: Update on food allergy research

Session recorded on September 15, 2017.

Speaker: Edwin Kim, MD

Viewers can earn credit by completing the posttest questions.

This video provides learners with information on the different modalities being studied for food allergy with regards to the proposed mechanisms, potential benefits, and potential risks. Learners will become familiar with the progress of research on the varying experimental treatments for food allergy including the non-FDA approved treatments and the potential for future FDA-approved treatments.

Target Audience

Practicing Allergists / Immunologists
Fellows-in-Training

Learning Objectives

After viewing the video recording, learners should be able to…

  • Describe the status of research on various experimental treatments for food allergy
  • Describe the common risks and benefits of experimental treatments for food allergy
  • Become familiar with the terms desensitization, sustained unresponsiveness, and tolerance with regards to food allergy treatment

Accreditation
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Commercial Support
There is no commercial support for this activity.

Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all educational planners, presenters, instructors, moderators, authors, reviewers, and other individuals in a position to control or influence the content of an activity must disclose all relevant financial relationships with any commercial interest that have occurred within the past 12 months. The ACCME defines a “commercial interest” as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified conflicts of interest must be resolved and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure be provided to the learners prior to the start of the activity.

Individuals with no relevant financial relationships must also inform the learners that no relevant financial relationships exist. Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI.

All identified conflicts of interest have been resolved.

Jay Portnoy, MD, Planner
Speaker, Honorarium: Thermofisher, Boehringer Ingelheim

Edwin Kim, MD, Speaker
Consultant, Honorarium: Aimmune Therapeutics, DBV Technologies

The following have no financial relationships to disclose:

Paul Dowling, MD, Planner

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
Course opens: 
09/15/2017
Course expires: 
09/14/2019
Cost:
$35.00
Rating: 
0

Edwin Kim, MD
University of North Carolina
School of Medicine

Accreditation
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Commercial Support
There is no commercial support for this activity.

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance

Accreditation Period

Course opens: 
09/15/2017
Course expires: 
09/14/2019

Price

Cost:
$35.00
Please login or create an account to take this course.